Sjogren's Syndrome


If Remission Is Our Goal, Rheumatology Must Embrace the Importance of Studying New Mechanisms

January 25, 2021

Alyssa Johnsen, MD, PhD, shares her insight on the importance of understanding key pathways that drive immune-mediated diseases, which can help rheumatologists develop more potent and specific therapies for patients with rheumatic disease.

Abatacept Fails Clinical Trial for Sjögren’s Syndrome

March 24, 2020

The use of abatacept did not lead to significant improvements in the disease status of patients with primary Sjögren's syndrome and in fact, it was essentially no better than placebo treatment, shows the first randomized, double-blind trial on abatacept for Sjögren’s.

Secondary Sjögren’s Syndrome in Lupus Increases with Age

October 07, 2019

Sjögren’s syndrome secondary to systemic lupus erythematosus (SLE) rises in frequency with age, affects around one-quarter of all people with systemic lupus, and, despite less internal organ involvement than in systemic lupus without Sjögren’s syndrome, is marked by a systemic inflammatory state with high levels of pro-inflammatory cytokines, say researchers writing in The Journal of Rheumatology  this month.